Name: Vico Therapeutics B.V. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

signInButton

SIGN IN

Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Please note, you are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry. Request a trial to unlock the full value of BCIQ.

REQUEST A FREE TRIAL

AcquiredOrMerged

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.

If you believe a company has been archived in error, please contact us at 

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.\nIf you believe a company has been archived in error, please contact us at \nsupport@biocentury.com\n.

Cat-H(AcquiredorMerged)

Historical deals and financings can be found by searching the organization's name in the BCIQ <DEALS> and <FINANCING> Modules.

Default (Company Type Blank)

CategoryHDefault (Company Type Blank)

NonBioPharma

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.

Cat-H(NonBioPharma)

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.\n

Vico Therapeutics B.V.

Venture Report: Curie.Bio’s fund; megarounds for Formation, EvolutionaryScale, BillionToOne

Strong week for VC deals includes Moonwalk launch, cross-border play OnCusp

McKinsey vet Dewhurst joins Lightrock

RNA editing of MECP2 for Rett syndrome

Sause named CEO of Roche Diagnostics

Mackison named CEO at Vico

Droia parlays cancer fund success into genetic disease-themed vehicle as Golumbeski joins as partner

With inaugural fund, Pureos looks to build up Swiss biotech ecosystem

With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

Kurma closes new fund at €160M, triple size of previous fund